Fujian Shengdi Pharmaceutical Co., Ltd.

This study tests a new drug called HRS9531 against an existing weight-loss drug, semaglutide, in 572 adults with obesity. Participants receive weekly injections for 52 weeks to see which drug works better for weight loss. The goal is to find a more effective treatment option for …

This study tests an experimental injection called HRS9531 in 200 obese adults with a type of heart failure where the heart pumps normally but is stiff. Participants receive either the drug or a placebo for 52 weeks. The goal is to see if the drug improves heart failure symptoms a…

This study tests an experimental drug called HRS-5632 in 203 adults with high levels of lipoprotein(a), a fatty substance that raises the risk of heart attacks and strokes. Participants receive either the drug or a placebo to see if it safely lowers their Lp(a) levels. The goal i…